Physician profile
Gabriel Rendon
NPI 1235161761
$40,821.65
in general payments reported to CMS, 2019-2025
41 companies · $2,671 in 2025
The $2,671 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,881 · 2020: $1,097 · 2021: $11K · 2022: $11K · 2023: $2,250 · 2024: $9,343 · 2025: $2,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,045 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,175 · Education: $31.00 · Travel and Lodging: $13.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,045.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,175.00 |
| Education | $31.00 |
| Travel and Lodging | $13.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,206.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,532.31 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $1,223.99 | 2019-2025 | Exalt Model D, Avvigo Guidance System, Resolution 360 Clip |
| Janssen Biotech, INC. | $798.78 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $710.19 | 2022-2025 | Dupixent |
| Medtronic Vascular, INC. | $618.33 | 2019 | |
| Pfizer INC. | $605.32 | 2019-2025 | |
| Daiichi Sankyo INC. | $494.07 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.08 | 2019-2025 | Xifaxan |
| Stryker Corporation | $354.25 | 2022 | |
| Genzyme Corporation | $334.38 | 2022-2025 | |
| Lilly USA, LLC | $316.89 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $315.53 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $310.28 | 2019-2024 | Clenpiq, Rebyota |
| Vivus LLC | $270.82 | 2021-2025 | Qsymia, Pancreaze |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $267.32 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $232.15 | 2021-2025 | Remicade, Stelara, Tremfya |
| Abiomed | $210.91 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $200.47 | 2021-2024 | Dificid, Zerbaxa |
| Medtronic, INC. | $163.74 | 2021-2024 | Endoflip, Gi Genius |
| Redhill Biopharma INC. | $132.05 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Genentech USA, INC. | $102.26 | 2019 | |
| Phathom Pharmaceuticals, INC. | $99.50 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $90.90 | 2025 | Rezdiffra |
| Ucb, INC. | $86.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $76.82 | 2019-2021 | |
| Braintree Laboratories, INC. | $63.91 | 2019-2021 | |
| Amgen INC. | $59.35 | 2021-2025 | Uplizna |
| Romark Laboratories, Lc | $47.47 | 2019-2020 | |
| Celltrion USA INC. | $47.13 | 2025 | Vegzelma |
| Ambu INC. | $43.36 | 2020 | |
| Abbott Laboratories | $39.96 | 2021-2025 | Jot Dx |
| Shionogi INC | $38.66 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $35.13 | 2022-2024 | Givlaari |
| Cook Medical LLC | $30.37 | 2019 | |
| Welch Allyn | $29.52 | 2021 | |
| Qol Medical, LLC | $25.83 | 2022 | |
| Intercept Pharmaceuticals, INC. | $25.16 | 2020 | |
| Shire North American Group INC | $20.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Rendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.